PURPOSE: To identify proteinases and growth factors abnormally expressed in human corneas of donors with diabetic retinopathy (DR), additional to previously described matrix metalloproteinase (MMP)-10 and -3 and insulin-like growth factor (IGF)-I. METHODS: RNA was isolated from 35 normal, diabetic, and DR autopsy human corneas ex vivo or after organ culture. Amplified cRNA was analyzed using 22,000-gene microarrays (Agilent Technologies, Palo Alto, CA). Gene expression in each diabetic corneal cRNA was assessed against pooled cRNA from 7 to 9 normal corneas. Select differentially expressed genes were validated by quantitative real-time RT-PCR (QPCR) and immunohistochemistry. Organ cultures were treated with a cathepsin inhibitor, cystatin C, or MMP-10. RESULTS: More than 100 genes were upregulated and 2200 were downregulated in DR corneas. Expression of cathepsin F and hepatocyte growth factor (HGF) genes was increased in ex vivo and organ-cultured DR corneas compared with normal corneas. HGF receptor c-met, fibroblast growth factor (FGF)-3, its receptor FGFR3, tissue inhibitor of metalloproteinase (TIMP)-4, laminin alpha4 chain, and thymosin beta(4) genes were downregulated. The data were corroborated by QPCR and immunohistochemistry analyses; main changes of these components occurred in corneal epithelium. In organ-cultured DR corneas, cystatin C increased laminin-10 and integrin alpha(3)beta(1), whereas in normal corneas MMP-10 decreased laminin-10 and integrin alpha(3)beta(1) expression. CONCLUSIONS: Elevated cathepsin F and the ability of its inhibitor to produce a more normal phenotype in diabetic corneas suggest increased proteolysis in these corneas. Proteinase changes may result from abnormalities of growth factors, such as HGF and FGF-3, in DR corneas. Specific modulation of proteinases and growth factors could reduce diabetic corneal epitheliopathy.
PURPOSE: To identify proteinases and growth factors abnormally expressed in human corneas of donors with diabetic retinopathy (DR), additional to previously described matrix metalloproteinase (MMP)-10 and -3 and insulin-like growth factor (IGF)-I. METHODS: RNA was isolated from 35 normal, diabetic, and DR autopsy human corneas ex vivo or after organ culture. Amplified cRNA was analyzed using 22,000-gene microarrays (Agilent Technologies, Palo Alto, CA). Gene expression in each diabetic corneal cRNA was assessed against pooled cRNA from 7 to 9 normal corneas. Select differentially expressed genes were validated by quantitative real-time RT-PCR (QPCR) and immunohistochemistry. Organ cultures were treated with a cathepsin inhibitor, cystatin C, or MMP-10. RESULTS: More than 100 genes were upregulated and 2200 were downregulated in DR corneas. Expression of cathepsin F and hepatocyte growth factor (HGF) genes was increased in ex vivo and organ-cultured DR corneas compared with normal corneas. HGF receptorc-met, fibroblast growth factor (FGF)-3, its receptor FGFR3, tissue inhibitor of metalloproteinase (TIMP)-4, laminin alpha4 chain, and thymosin beta(4) genes were downregulated. The data were corroborated by QPCR and immunohistochemistry analyses; main changes of these components occurred in corneal epithelium. In organ-cultured DR corneas, cystatin C increased laminin-10 and integrin alpha(3)beta(1), whereas in normal corneas MMP-10 decreased laminin-10 and integrin alpha(3)beta(1) expression. CONCLUSIONS: Elevated cathepsin F and the ability of its inhibitor to produce a more normal phenotype in diabetic corneas suggest increased proteolysis in these corneas. Proteinase changes may result from abnormalities of growth factors, such as HGF and FGF-3, in DR corneas. Specific modulation of proteinases and growth factors could reduce diabetic corneal epitheliopathy.
Authors: M Saghizadeh; D J Brown; R Castellon; M Chwa; G H Huang; J Y Ljubimova; S Rosenberg; K S Spirin; R B Stolitenko; W Adachi; S Kinoshita; G Murphy; L J Windsor; M C Kenney; A V Ljubimov Journal: Am J Pathol Date: 2001-02 Impact factor: 4.307
Authors: K S Spirin; A V Ljubimov; R Castellon; O Wiedoeft; M Marano; D Sheppard; M C Kenney; D J Brown Journal: Invest Ophthalmol Vis Sci Date: 1999-12 Impact factor: 4.799
Authors: Y Kaji; T Usui; T Oshika; M Matsubara; H Yamashita; M Araie; T Murata; T Ishibashi; R Nagai; S Horiuchi; S Amano Journal: Invest Ophthalmol Vis Sci Date: 2000-02 Impact factor: 4.799
Authors: O Rechardt; O Elomaa; M Vaalamo; K Pääkkönen; T Jahkola; J Höök-Nikanne; R M Hembry; L Häkkinen; J Kere; U Saarialho-Kere Journal: J Invest Dermatol Date: 2000-11 Impact factor: 8.551
Authors: Dhruv Sareen; Mehrnoosh Saghizadeh; Loren Ornelas; Michael A Winkler; Kavita Narwani; Anais Sahabian; Vincent A Funari; Jie Tang; Lindsay Spurka; Vasu Punj; Ezra Maguen; Yaron S Rabinowitz; Clive N Svendsen; Alexander V Ljubimov Journal: Stem Cells Transl Med Date: 2014-07-28 Impact factor: 6.940
Authors: Andrei A Kramerov; Mehrnoosh Saghizadeh; Hao Pan; Andrea Kabosova; Mathias Montenarh; Khalil Ahmed; John S Penn; Candy K Chan; David R Hinton; Maria B Grant; Alexander V Ljubimov Journal: Am J Pathol Date: 2006-05 Impact factor: 4.307
Authors: Mehrnoosh Saghizadeh; Andrei A Kramerov; Fu-Shin X Yu; Maria G Castro; Alexander V Ljubimov Journal: Invest Ophthalmol Vis Sci Date: 2009-11-20 Impact factor: 4.799
Authors: Mark A Horswill; Malathi Narayan; Debra J Warejcka; Lisa A Cirillo; Sally S Twining Journal: Exp Eye Res Date: 2008-01-12 Impact factor: 3.467